Genomic Collaboration and Licensing Deals 2016-2024


Genomics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of genomic deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 948 genomic deals announced since 2016 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genomic dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genomic dealmaking since 2016.

Chapter 3 provides an overview of the leading genomic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse genomic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Genomic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genomic trends and structure of deals entered into by leading biopharma companies worldwide.

Genomic Collaboration and Licensing Deals includes:
•    Trends in genomic dealmaking in the biopharma industry
•    Directory of genomic deal records covering pharmaceutical and biotechnology
•    The leading genomic deals by value
•    Most active genomic licensing dealmakers

Genomic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse genomic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in genomic dealmaking
2.1. Introduction
2.2. Genomic deals over the years
2.3. Most active genomic dealmakers
2.4. Genomic deals by deal type
2.5. Genomic deals by therapy area
2.6. Genomic deals by industry sector
2.7. Deal terms for genomic deals
2.7.1 Genomic deals headline values
2.7.2 Genomic deal upfront payments
2.7.3 Genomic deal milestone payments
2.7.4 Genomic royalty rates

Chapter 3 – Leading genomic deals
3.1. Introduction
3.2. Top genomic deals by value

Chapter 4 – Most active genomic dealmakers
4.1. Introduction
4.2. Most active genomic dealmakers
4.3. Most active genomic deals company profiles

Chapter 5 – Genomic contracts dealmaking directory
5.1. Introduction
5.2. Genomic contracts dealmaking directory

Chapter 6 – Genomic dealmaking by technology type

Deal directory

Deal directory – Genomic deals by company A-Z
Deal directory – Genomic deals by deal type
Deal directory – Genomic deals by therapy area

Deal type definitions

About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Genomic deals since 2016
Figure 2: Active genomic dealmaking activity – 2016 - 2024
Figure 3: Genomic deals by deal type since 2016
Figure 4: Genomic deals by therapy area since 2016
Figure 5: Genomic deals by industry sector since 2016
Figure 6: Genomic deals with a headline value
Figure 7: Genomic deals with an upfront value
Figure 8: Genomic deals with a milestone value
Figure 9: Genomic deals with a royalty rate value
Figure 10: Top genomic deals by value since 2016
Figure 11: Most active genomic dealmakers 2016 - 2024
Figure 12: Genomic deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

1CellBiO, 2bPrecise, 2seventy bio, 3 Sisters Surrogacy, 4baseCare, 4bases, 10X Genomics, 22nd Century, A*STAR Agency for Science, Technology and Research, A*STAR Bioinformatics Institute, A*STAR Genome Institute of Singapore, Abbvie, AbCellera Biologics, Abramson Cancer Center, Absorption Systems, Academia Sinica, Accelerated Cure Project for MS, Accelerate Technologies, AccessDx Laboratory, Access to Comprehensive Genomic Profiling Coalition, AccuGenomics, AccuStem Sciences, Acerta Pharma, Acrobat Genomics, Active Motif, Adaptive Biotechnologies, ADInstruments, Admera Health, Adrestia, Advanced Analytical Technologies, Aevi Genomic Medicine, AgBiome, Agendia, Agilent Technologies, Agios Pharmaceuticals, Agribody Technologies, Agriplex Genomics, AiLife Diagnostics, Aitbiotech, Akadeum Life Sciences, Albany Molecular Research, Alexion Pharmaceuticals, AllCells, Alloy Therapeutics, Almac Diagnostics, Almaden Genomics, Alnylam Pharmaceuticals, Altor BioScience, Amazon Web Services, Ambry Genetics, American Physiological Society, American Skin Association, American Society of Clinical Oncology (ASCO), American Type Culture Collection (ATCC), Amgen, Amoy Diagnostics, Amplicon Express, Analytical BioSciences, AnchorDx, Angsana Molecular & Diagnostics, Apollomics, Appistry, Applied Biosystems, Applied Cells, Aptorum Group, Arbor Biotechnologies, ArcherDX, ARCHIMEDlife, Arcturus Therapeutics, Ares Genetics, Ares Life Sciences, Arima Genomics, ARUP Laboratories, Asa Ren, Aslan Pharma, Assistance Publique-Hôpitaux de Paris, Associazione Poic e Dintorni APS, Astellas Pharma, AstraZeneca, AtlasXomics, Atreca, ATUM, Auria Biobank, Avance Biosciences, Avera Health, Avera Heart Hospital of South Dakota, B-MoGen Biotechnologies, Baheal Pharmaceutical, Bank of America, Banner Health, Basepair, BASF, Battelle, Baxalta, Bayer, Bayer CropScience, Baylor College, Baylor College of Medicine, Baylor Genetics, Baylor Miraca Genetics Laboratories, BC Platforms, Beckman Coulter, Becton Dickinson, Beijing Genomics Institute (BGI), Benson Hill Biosystems, Berkeley Lights, Berry Genomics, Beth Israel Deaconess Medical Center, BGI, BGI Americas, BigOmics Analytics, Bill and Melinda Gates Foundation, Bio-Medical Science, Bio-Rad Laboratories, Bio-Techne, BioBright, Biocartis, Biocept, Biodesix, BioDiscovery, Biogen, BioIntelliSense, BioLegend, BioLizard, BioMap, BioMarin Pharmaceutical, BioMed X Innovation Center, Biomillenia, BiomX, BioNano Genomics, Biosplice, BioTheranostics, Bioz, BitBiome, Blockchain Global, Bluebee, Bluebird Bio, Blue Cross Blue Shield Association, BluePen Biomarkers, Blueprint Genetics, BlueRock Therapeutics, Boca Biolistics, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Boreal Genomics, BostonGene, Boston Veterans Affair Research Institute, Brigham and Women's Hospital, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Broad Clinical Labs, Broad Institute, Buhler, Burning Rock, C2i Genomics, California Institute for Regenerative Medicine, California Institute of Technology, Calyxt, Cambridge Cancer Genomics, Cambridge Epigenetix, CAMP4 Therapeutics, Canadian Cancer Society, Canadian Council, Cancer Molecular Diagnostic Laboratory, Cancer Research Horizons, Cancer Research Institute, Cancer Research UK, Canopy Biosciences, CareDx, Caribou Biosciences, Caris Life Sciences, Cartana, CasZyme, Celemics, Celgene, Cell and Gene Therapy Catapult, CellChorus, Cellecta, Cellgen Diagnostics, Cell Medica, Cell Mogrify, Cellnetix, Cellworks, Celmatix, Celsius Therapeutics, Center for Aquaculture Technologies, Center for Forensic Science Research & Education, Center for Molecular Medicine, Centers for Disease Control and Prevention, Centogene, Centre For Proteomic & Genomic Research, Centre for Research in Agricultural Genomics, Centre Leon Berard, Cerba Research, CerebraCell, Cergentis, Ceva Sante Animale,, CGA 369, Champions Oncology, Chan Zuckerberg Initiative, Charcot-Marie-Tooth Association, Charite Universitatsmedizin Berlin, Charles River Laboratories, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Orange County, Children's Hospital of Philadelphia, Children's Medical Research Institute, Children's Minnesota, Children’s Hospital Oakland Research Institute (CHORI), Chinese Academy of Agricultural Science, Christian Doppler Research Association, Chroma Medicine, Chugai Pharmaceutical, CHU Sainte-Justine, Circuit Clinical, Circulogene, Citizens United for Research in Epilepsy, City of Hope, Clearbridge Biomedics, Cleveland Clinic, Cleveland Diagnostics, Clinical Genomics, Clinical Outcomes Tracking and Analysis, Cloudera, CloudHealth Genomics, Clover Therapeutics, CMT Research Foundation, Coastar Therapeutics, Codexis, Codigo46, Cofactor Genomics, Cohen Veterans Bioscience, Color, Colorado Center for Personalized Medicine, Columbia University, Columbia University Medical Center, CombiGene, Complete Genomics, ConcertAI, Concr, Congenica, Contextual Genomics, CoreBiome, Coriell Life Sciences, Corteva Agriscience, CosmosID, COTA, Covaris, Crohn's and Colitis Foundation of America, Crown Bioscience, CSI Laboratories, Culmination Bio, Curable, CureMatch, Curetis, CureVac, Curio Genomics, CvergenX, Cyclica, CYTOVIA Therapeutics, Cytox, Daiichi Sankyo, Dana-Farber Cancer Institute, Dante Genomics, Dante Labs, Dartmouth-Hitchcock Medical Center, DaRui Biotech, Data Tecnica International, Datavant, Decipher Biosciences, Decode Health, DEEP 6 AI, Deep Genomics, Deerfield Management, DefiniGEN, Denali Therapeutics, Dendreon, Denka, Denka-KEW Genomics, Department of Health - Abu Dhabi, Department of Veterans Affairs, Desktop Genetics, DestiNA Genomics, Devyser Diagnostics, Dicom Systems, DiscoveRx, Discovery Life Sciences, Diversigen, DNA Link, DNAmito, DNAnexus, DNA Script, Dolomite Bio, Dovetail Genomics, Dow AgroSciences, DrChrono, Duke-NUS Graduate Medical School Singapore, Duke University, Duke University Health System, DuPont, DuPont Pioneer, DxTerity, e-NIOS, Eagle Genomics, ECOG-ACRIN Cancer Research Group, Edico Genome, Editas Medicine, Eisai, Eisai Inc, Element Biosciences, Elevation Oncology, Eli Lilly, Elsevier, Elucigene, EMBRAPA, EMD Serono, Emedgene, Emendo Biotherapeutics, EncrypGen, Endocanna Health, ENPICOM, Ensoma, Enterome Bioscience, Enzyvant Science, Eone-Diagnomics Genome Center, Epic Sciences, Epicypher, Epilepsy Society, Epivax, Erasmus University Medical Center, ERS Genomics, Etubics, Euformatics, Eureka Eurostars, Eurofins Genomics, Eurofins Scientific, Euroimmun, European Equity Partners, European Organization for Research and Treatment of Cancer, European Union, Evolva, Evonetix, Evotec, Evvy, Exact Sciences, Exonics Therapeutics, Exploragen, ExxonMobil, F1 Oncology, Fabric Genomics, Factorial Biotechnologies, Factorial Diagnostics, Falco, FDNA, Ferring Pharmaceuticals, Fertility SOURCE Companies, FinnGen, First Databank, First Genetics JCS, Flare Therapeutics, Flatiron Health, FlowJo, Fluent BioSciences, Fluidigm, FLX Bio, FMC, Fortis Life Sciences, Foundation for Innovative New Diagnostics, Foundation for the Children of the Californias, Foundation Medicine, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, Freenome, French National Institute for Agricultural Research, Front Range Biosciences, Fudan University, Fujitsu Laboratories, Fulcrum Therapeutics, Fulgent Genetics, Fusion Genomics, G+FLAS Life Sciences, G42 Healthcare, Ganymede Bio, GC Genome, GDM Seeds, GEDmatch, Geisel School of Medicine at Dartmouth, Gemini Therapeutics, Gencove, GeneBay, GeneCentric Therapeutics, Genective, GeneData, GeneDX, Geneformics, Genentech, GenePeeks, General Genomics, Geneseeq, Genestack, Genetica, Genetic Technologies, Genetiks, Genetron Health, Geneva University Hospitals, Genewiz, Geneyx, Genialis, Genolution, Genome BC, Genome Canada, GenomeDx, Genome Insight, Genome Institute of Singapore, Genome Medical, Genomenon, Genome Prairie, Genomic Biopharma, Genomic Health, Genomics, Genomics England, Genomic Testing Cooperative, Genomic Vision, Genomind, Genoox, Genoptix, GenoScreen, Genosity, GenScript Biotech, Genspace, Gentris, Genuity Science, Genus, GenVec, GenXys, Genzeva, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, German Cancer Research Center, Gilead Sciences, Ginkgo BioWorks, Global Genomics Group, GNS Healthcare, Goldfinch Bio, Google, Government of Canada, GPBio, Grail, Greater Paris University Hospitals, Gretel, Gritstone Bio, GSK, Guardant Health, Gusto Global, H3 Biomedicine, Hackensack Meridian Health, Hackensack University Medical Center, Hamad Bin Khalifa University, Hamilton Company, Hamilton Robotics, Hannover Medical School, HaploX, Harvard Medical School, Harvard Stem Cell Institute, Harvard University, Healthcare Global Enterprises, HeartScore, Helen F Graham Cancer Center, Heligenics, Helix, Helmholtz Zentrum Munchen, Henry Ford Health System, HepaTx, Hereditary Neuropathy Foundation, Hitachi High-Technologies Corporation, HMNC Brain Health, Homology Medicines, Horizon Discovery, Horizon Healthcare Services, Horizon Pharma plc, Hospital for Sick Children, Hospital for Special Surgery, HTG Molecular Diagnostics, Huawei, Hudson-Alpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology, Human Cell Atlas, Human Longevity, Hummingbird Bioscience, Hummingbird Diagnostics, Huntsman Cancer Institute, IBM, IBM Watson Health, Icahn School of Medicine at Mount Sinai, IDbyDNA, Idengene, Illumina, ILUM Health Solutions, Imagene Labs, IMBdx, Immunai, Immune Design, Immunex, Imperial Innovations, In-Depth Genomics, In-Q-Tel, IncellDx, Incyte, Indiana University, Indivumed, IndyGeneUS AI, Information Technology for Translational Medicine, Inivata, Innoplexus, Innovate UK, Innovative Genomics Initiative (IGI), Inova Genomics Laboratory, Inova Translational Medicine Institute, Inovio Pharmaceuticals, Inserm, Insitro, InSphero, Institut Curie, Institute for Genome Statistics and Bioinformatics, Institute of Human Genetics, Institut Gustave Roussy, Institut Pasteur, Integra, Integra Biosciences, Integrated DNA Technologies, Intel, Intellia Therapeutics, Intelligence Advanced Research Projects Activity (IARPA), Intelliseq, Intercept Pharmaceuticals, Intermountain Precision Genomics, International Center for Genetic Engineering and Biotechnology, International Myeloma Foundation, International Rice Research Institute, InterSystems, inviCRO, Invitae, InVivoScribe, Ionis Pharmaceuticals, Ipsen, IQVIA, iReceptor Plus, ISOThrive, Israeli National Authority for Technological Innovation, Jackson Laboratory, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, JASE Health, Jeffrey Modell Foundation, Johns Hopkins University, Johnson & Johnson Innovation, John Wayne Cancer Institute, Jumpcode Genomics, Juno Therapeutics, Kaiima Bio-Agritech, Kailos Genetics, Kanteron Systems, Karolinska Institute, Kartos Therapeutics, Kazusa DNA Research Institute, Keck Graduate Institute of Applied Life Sciences, Keck School of Medicine of USC, KEW, Keygene, King Abdullah International Research Center, KingMed Diagnostics, Kiromic Biopharma, Kleiner Perkins Caufield & Byers, Knudra Transgenics, KolGene, Konica Minolta Precision Medicine, KPMG, Kura Oncology, Kyowa Hakko Kirin, Kytopen, Laboratoire Cerba, Laboratorio Curie, Laboratory Corporation of America, Lantern Pharma, LaserGen, Latvian Institute of Organic Synthesis, Lee Moffitt Cancer Center, Lenovo, Leona M and Harry B Helmsley Charitable Trust, Lesaffre, Les Laboratoires Servier, Leukemia & Lymphoma Society, Lexent Bio, LGC, LGS Foundation, Lieber Institute, LifeLabs Medical Laboratory Services, LifeMap Sciences, LifeNome, LifeOmic, Life Raft Group, Linus Biotechnology, Liquid Biotech USA, LMU University Hospital Munich, Locus Biosciences, Lodo Therapeutics, LogicBio Therapeutics, Longenesis, Lonza, Loxo Oncology, Lunaphore, Lung Cancer Research Foundation, Macrogen, Mainz Biomed, MapKure, Marina Biotech, Massachusetts General Hospital, Massachusetts Institute of Technology, Mass General Brigham, Massive Bio, Mayo Clinic, MD Anderson Cancer Center, Medaffcon, med fusion, Medgenics, MedGenome, Medical College of Wisconsin, Medical University of Graz, Medicinal Genomics, MEDiC Life Sciences, MedStar Health Research Institute (MHRI), Meharry Medical College, Meiogenix, Memorial Sloan Kettering Cancer Center, Menarini Silicon Biosystems, Mercachem, Merck and Co, Merck KGaA, Merus, Metabolon, MGI Pharma, MGI Tech, Michael J Fox Foundation, Michelson Center, Microba Life Sciences, Microbiotica, MicroGenDX, MicroMGx, Micronoma, Microsoft, Milner Therapeutics Institute and Consortium, MindImmune Therapeutics, Mirna Therapeutics, Miroculus, Mirus Bio, Mission Bio, Moderna, Molbio Diagnostics, Molecular Health, Moleculera Labs, Monsanto, Montreal Heart Institute, MorphoSys, Moss Genomics, Mount Sinai Services, MP Group, Multiplex Genomics, Munich Leukemia Laboratory, Muscular Dystrophy Association, Myriad Genetics, Myrtelle, MyVytalics, N-of-One, NABsys, Nalagenetics, Namocell, Nankai Hospital, NanoCellect Biomedica, NanoString Technologies, NantHealth, NantKwest, NantWorks, Nanyang Technological University, Nashville Biosciences, Natera, National Cancer Center, National Cancer Center of Japan, National Cancer Center of South Korea, National Cancer Centre Singapore, National Cancer Institute, National Foundation for Cancer Research, National Geographic, National Health Service, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of General Medical Sciences, National Institutes of Health, Navican, Nebraska Medicine, Nebula Genomics, NEC, Negen, Neochromosome, Neogen, Neogenomics, Neptune Technologies & Bioressources, Netherlands Cancer Institute, Neuron23, Newborn Screening Ontario, New England Biolabs, NewStem, New York Genome Center (NYGC), New York Medical College, New York State Department of Health, New York University School of Medicine, NGeneBio, NMI Natural and Medical Sciences Institute, Nomad Bioscience, Nonacus, Normunity, North Med, Northwestern University, Novartis, NovellusDx, Novigenix, Novogene, Novo Nordisk, Nrgene, Nucleix, NuGen Technologies, NuProbe, Nvidia, NYU Grossman School of Medicine for Preclinical and Clinical Research, Octant, Ohio State University, Oklahoma Medical Research Foundation, Olink Bioscience, OMAPiX, Omico, Omniome, OncoDNA, Oncology Research Information Exchange Network, OncoMed Pharmaceuticals, Oncompass Medicine, Oncoshot, OncXerna Therapeutics, One BioMed, One Biosciences, One Codex, One Lambda, Oneome, ONK Therapeutics, Onramp Bioinformatics, Ontario Institute for Cancer Research, OpenBench, Open Commons Consortium, Open Medicine Institute, Opentrons Labworks, OpGen, Opisafe, OPKO Health, Orchid Cellmark, Oregon Health Sciences University, OrigiMed, Origin Agritech, Oryzon, Ovation, Owkin, Oxford Biodynamics, Oxford Genetics, Oxford Nanopore Technologies, Ozette Technologies, Pacific Biosciences, Paige, Pairwise Plants, Pancreatic Cancer Action Network, Pancreatic Cancer Collective, Paradigm, Paragon Genomics, Parexel, Parse Biosciences, Partek, Partners HealthCare, Path BioAnalytics, PathGroup, PathoQuest, Pathway Genomics, Pennsylvania State University, PerkinElmer, Personal Genome Diagnostics, Personalis, PetaGene, Pfizer, Pharmatest Services, Pharnext, Phase Genomics, Phenome Networks, Philips, Pierian, PierianDx, Pillar Biosciences, Pioneer Hi-Bred, Plant Bioscience Limited, PlumCare, Pluristem Therapeutics, Pluristyx, Portable Genomics, Poseida Therapeutics, PPD, Precision Biologics, Precision BioSciences, Precision NanoSystems, Predicine, Premier Inc, Prenetics, Prepaire Labs, Prescient Medical, PreventionGenetics, Princess Margaret Hospital, Progknowse, Promega, Prophase Labs, Prostate Cancer Clinical Trials Consortium, Proteic Bioscience, Proteona, Proteus Genomics, Pryzm Health, Q2 Solutions, Qatar Foundation, Qiagen, Quanterix, QuantumDx, Quark Pharmaceuticals, Quest Diagnostics, Quintara Biosciences, R-Biopharm, rAAVen Therapeutics, Rady Children's Institute for Genomic Medicine, Rare Genomics Institute, ReadCoor, Realm IDx, Recombia Biosciences, Regeneron Genetics Center, Regeneron Pharmaceuticals, Repertoire Genesis, Replicate Bioscience, Replicel Life Sciences, Repositive, Resilient Biotics, Resolve Biosciences, Reveal Genomics, Revvity, Rice University, RIKEN Center for Integrative Medical Sciences, RIKEN Research Institute, Ripe Technology, Robert H. Lurie Comprehensive Cancer Center, Roche, Roche Diagnostics, Rockefeller University, Rosetta Genomics, Royal Philips Electronics, RPRD Diagnostics, RTI International, Rubicon Genomics, Rutgers University, Ryailti, S2 Genomics, Salk Institute, Salud Interactiva, Sana Biotechnology, Sanford Burnham Institute, Sangamo Therapeutics, Sanguine, Sanofi, Saol Therapeutics, Saphetor, Sapio Sciences, Sarah Cannon Research Institute, Sarepta Therapeutics, Scale Biosciences, Scarab Genomics, Scipher Medicine, Scripps Research Institute, Scripps Translational Science Institute, Secarna Pharmaceuticals, Second Genome, Sema4, Semmelweis University, Sentieon, SenzaGen, Seoul National University, Seqster, Sequentify, SeQure Dx, SeqWell, Seracare Life Sciences, Seres Therapeutics, Serotiny, Seven Bridges Genomics, Shanghai ChemPartner, Shanghai Institutes of Preventative Medicine, Sheba Medical Center, Shivom, Silicon Biosystems, Singlera Genomics, Singleron Biotechnologies, Singular Genomics Systems, Sohm, SOLTI, SolveBio, SomaGenics, SomaLogic, Sonic Healthcare, SOPHiA Genetics, Spanish National Cancer Research Centre, Spatial Genomics, Spectrum Pharmaceuticals, SPT Labtech, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, Stem Genomics, Stem Pharm, Stockholm University, Strata Oncology, Streck Laboratories, Structural Genomics Consortium, Sumitovant Biopharma, Sunnybrook Research Institute, Sunquest Information Systems, SunTerra Biotechnology, Susan G. Komen for the Cure, Swift Biosciences, Swiss Institute of Bioinformatics (SIB), Syapse, Syngenta, Synthego, Synthetic Genomics, Syros Pharmaceuticals, Sysmex, Sysmex Inostics, Taconic Biosciences, Taiwan Precision Medicine Initiative, Takara Bio, Takeda Pharmaceutical, Takeda Ventures, Tango Therapeutics, TARGET PharmaSolutions, Tavros Therapeutics, Taysha Gene Therapies, Tecan, Technology University Dresden, Tempus, Tenet Diagnostics, Tesis Biosciences, Tessera Therapeutics, The Donor Solution, The New York Stem Cell Foundation, The Parker Institute For Cancer Immunotherapy, Theraly Fibrosis, Thermo Fisher Scientific, The Silverstein Foundation for Parkinson's, The University of Chicago Medicine, Thomas Jefferson University, Thrive Bioscience, TME Research, Tokyo Medical and Dental University, TOMA Biosciences, Tow Foundation, Toyota Motor, TP Therapeutics, Trajan Scientific and Medical, Transcriptic, Transcriptome Sciences, Transgene, Transgenomic, Translational Drug Development, Translational Genomics Research Institute, Translational Software, Transnetyx, Transomic Technologies, Transplant Genomics, TrovaGene, TTP LabTech, Tute Genomics, Twinstrand Therapeutics, Twist Bioscience, Two Blades Foundation, uBiome, UbiQ, UK Biobank, Ultima Genomics, Ultivue, Umoja Biopharma, Unilabs, Univeristy of Durham, University College London, University Health Network, University Hospital Heidelberg, University Hospital of Leuven, University of Adelaide, University of Alabama at Birmingham, University of Birmingham, University of Bonn, University of British Columbia, University of Buffalo, University of Calgary, University of California, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of California Santa Cruz, University of Colorado Denver, University of Florida, University of Greifswald, University of Hong Kong, University of Illinois, University of Illinois Urbana-Champaign, University of Iowa, University of Lausanne, University of Leuven, University of Manchester, University of Massachusetts, University of Miami, University of Michigan, University of Michigan Medical School, University of Minnesota, University of Ottowa, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Rostock, University of Sydney, University of Texas Southwestern Medical Center, University of Tokyo, University of Tubingen, University of Utah, University of Verona, University of Virginia, University of Washington, University of Western Australia, University of Wisconsin, University of Wisconsin Carbone Cancer Center (UWCCC), US Oncology, Utah Genome Project, Vanderbilt University, Varian Medical Systems, Vectalys, Ventana Medical Systems, Veracyte, Verge Genomics, Veritas, Veritas Genetics, Verogen, Vertex Pharmaceuticals, Victoria University, VieCure, Vir Biotechnology, Vitaccess, Viviphi, Vivo Biosciences, Vizgen, Volta Labs, Voyager Therapeutics, Wageningen University, Washington University in St Louis, Watchmaker Genomics, WaVe Lifesciences, Weihai Weigao Medical Devices, Weill Cornell Medical College, Wellcome Trust Sanger Institute, Western Digital, Wuxi Apptec Laboratory Services, WuXi NextCODE Genomics, Xcell Biosciences, Xencor, Xpressomics, Xpress Technologies, Yale School of Medicine, Yale University, Yeda Research and Development Company, Yield10 Bioscience, ZAI Laboratory, Zymergen, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.